➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Merck
McKinsey
Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Oxazepam - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for oxazepam and what is the scope of patent protection?

Oxazepam is the generic ingredient in three branded drugs marketed by Actavis Elizabeth, Am Therap, Frontida Biopharm, Ivax Sub Teva Pharms, Mylan, Sandoz, Watson Labs, Watson Labs Teva, Alpharma Us Pharms, Quantum Pharmics, Parke Davis, and Sun Pharm Industries, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for oxazepam. Four suppliers are listed for this compound.

Drug Prices for oxazepam

See drug prices for oxazepam

Recent Clinical Trials for oxazepam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Drug Abuse (NIDA)Phase 1
Embera NeuroTherapeutics, Inc.Phase 1
National Institute on Drug Abuse (NIDA)Phase 0

See all oxazepam clinical trials

Pharmacology for oxazepam
Drug ClassBenzodiazepine
Medical Subject Heading (MeSH) Categories for oxazepam
Paragraph IV (Patent) Challenges for OXAZEPAM
Tradename Dosage Ingredient NDA Submissiondate
SERAX CAPSULE;ORAL oxazepam 015539
SERAX TABLET;ORAL oxazepam 015539

US Patents and Regulatory Information for oxazepam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Am Therap OXAZEPAM oxazepam CAPSULE;ORAL 071956-001 Mar 3, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Ivax Sub Teva Pharms OXAZEPAM oxazepam CAPSULE;ORAL 070943-001 Aug 3, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Am Therap OXAZEPAM oxazepam CAPSULE;ORAL 071955-001 Mar 3, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva OXAZEPAM oxazepam CAPSULE;ORAL 072952-001 Sep 28, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oxazepam

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-006 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-004 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Merck
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.